Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 182 for your search:
Drug:
irinotecan hydrochloride
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
Phase:
Phase IV
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
COLOGEN
, NCT00138060
2.
Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CHUL-BIO-COLON
, RECF0356, INCA-RECF0356, NCT00559676
3.
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
Over 21
Sponsor:
Other
Protocol IDs:
PK01/16/08
, NCT00808184
4.
Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
FRE-FNCLCC-ACCORD-11/0402
, EU-20512, NCT00112658
5.
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
Haema CBF SCLC UK/AS 01
, NCT00168896
6.
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
20 and over
Sponsor:
Other
Protocol IDs:
JACCRO GC-05
, NCT00639327
7.
Study to Evaluate NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
08-PIR-03
, NCT00856375
8.
Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase:
Phase III, Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UKM-MRC-FOCUS3-CR12
, FOCUS 3 - CR12, EUDRACT-2008-008323-15, EU-20960, NCT00975897
9.
Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCCTG-N0147
, ECOG-N0147, N0147, NCT00079274
10.
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
75 and under
Sponsor:
Other
Protocol IDs:
FFCD 2000 – 05
, CET 815, NCT00126256
11.
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
AERO-R98
, NCT00189657
12.
Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 4) Versus High-Dose Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 7) Followed by Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Colorectal Cancer Metastatic to the Liver
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GERCOR-C02-1
, GERCOR-C02-1-MIROX, EU-20567, SANOFI-GERCOR-C02-1, NCT00268398
13.
Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-C80405
, C80405, SWOG-C80405, NCT00265850
14.
Phase III Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan Hydrochloride in Combination With Radiotherapy in Patients With Newly Diagnosed, Intermediate-Risk Rhabdomyosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI
Protocol IDs:
COG-ARST0531
, NCT00354835, ARST0531
15.
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CRCST-L-0001
, NCT00349492
16.
Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
CTRU-PICCOLO-MO-05-7289
, EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870
17.
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
FIRE-3
, NCT00433927
18.
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
LSO-OL006
, NCT00440310
19.
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181122
, NCT00457691
20.
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
Other
Protocol IDs:
CT/05.16
, NCT00469443
21.
Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy (Treatment Arm III Closed to Accrual as of 4/20/2009)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0600
, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
22.
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EFC10262
, EudraCT 2007-000820-42, NCT00561470
23.
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CSMS995AIC04
, NCT00582426
24.
Phase III Randomized Study of Second-Line Combination Chemotherapy With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy With Bevacizumab
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
GONO-BEBYP-ASL607LIOM03
, GONO– ASL607LIOM03, GONO-AIFA - FARM5C4FB4, EUDRACT:2007-002886-11, NCT00720512
25.
Phase III Randomized Study of FOLFOXIRI Combination Chemotherapy and Bevacizumab Versus FOLFIRI Combination Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Unresectable Metastatic Colorectal Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
GONO-TRIBE
, TRIBE, ASL608LIOM04, EUDRACT:2008-001537-10, NCT00719797
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
